|
| Exchange Disseminated Time 28/12/2016 10:47:10 | Cadila Healthcare Ltd has informed BSE that :
"With reference to a news appearing in the media this morning, we wish to state as under:
We wish to clarify that this matter very specifically relates to an Untitled Letter issued by the USFDA to Zydus Discovery DMCC (a 100% subsidiary of Cadila Healthcare Ltd.) and not a Warning Letter. The letter is related to a product promotion of a drug which is not marketed in USA and currently marketed only in India. We have already taken the necessary actions to respond to this letter.
As per the USFDA website, "Unlike a warning letter, an Untitled Letter does not include a statement warning that failure to promptly correct a violation may result in an enforcement action". |
|
|